Abiopharma

BOSS Zhipins Ongoing Share Repurchases Cross the RMB1 Billion Mark in 2026

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

KE Holdings Inc. to Hold Annual General Meeting on June 12, 2026

Net Asset Value(s)

Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

Communiqué de presse : Cenrifki de Sanofi (tolebrutinib) recommandé par le Comité des médicaments à usage humain (CMUH) pour être approuvé par l’UE pour le traitement de la sclérose en plaques secondairement progressive sans poussées

Changes To The Composition Of The Board Of Directors And Board Committees

GRAVITY ANNOUNCES FILING OF ANNUAL REPORT ON FORM 20-F FOR FISCAL YEAR 2025

Change - Announcement Of Cessation :: Resignation Of Independent And Non-Executive Director

Elizabeth Moellering Named General Counsel and Corporate Secretary of Maximus